Carbamazepine triggered Stevens-Johnson syndrome with gastrointestinal and renal system involvement: a case report

Zeena Salwa; Tanha Tazmin

doi:10.18203/2349-3291.ijcp20243093

Authors

Zeena Salwa Department of Paediatrics and Child Development Centre, Square Hospitals Limited, Dhaka, Bangladesh
Tanha Tazmin Department of Child Development Centre, Square Hospitals Limited, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2349-3291.ijcp20243093

Keywords:

Stevens-Johnson syndrome, Toxic epidermal necrolysis, Skin, Mucous membrane, Carbamazepine

Abstract

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare but life-threatening condition characterized by severe skin and mucosal involvement. Recently, we encountered four cases of Stevens-Johnson syndrome (SJS), three of which were associated with carbamazepine use. This report focuses on one of these cases to highlight the risks associated with this medication. Carbamazepine (CBZ) is recognized as one of its common triggers. This report discusses one of these cases involving an eight-year-old boy weighing 23.3 kg, with a one-year history of epilepsy initially managed with oral sodium valproate, experienced frequent seizures. Consequently, sodium valproate was discontinued, and carbamazepine was started at a dose of 150 mg twice daily. After one week, the dosage was increased to 150 mg in the morning and 300 mg at night. Forty-two days post-initiation of carbamazepine, the patient exhibited fever, cough, and malaise, followed by skin rashes affecting the oral mucosa and eyes three days later. He then developed profuse oral secretions, bloody diarrhea, microscopic hematuria, and albuminuria. The administration of carbamazepine was immediately halted, and the patient was managed in the Pediatric Intensive Care Unit (PICU) by a multidisciplinary team. He achieved full recovery after 35 days. The objective of this case report is to raise awareness of carbamazepine as a potential trigger for SJS, differentiate between Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and discuss the risk factors, differential diagnosis, and management of SJS/TEN, which often requires a multidisciplinary approach in a pediatric intensive care unit (PICU).

Metrics

Metrics Loading ...

References

Joyee JC. Vesiculobullous Disorders, In Nelson textbook of Pediatrics, 21st edition. 2020:3080-90.

Jha N, Alexander E, Kanish B, Badyal DK. A study of cutaneous adverse drug reactions in a tertiary care center in Punjab. Indian Dermatol Online J. 2018;9(5):299-303.

National organization for rare diseases. fact sheet: Stevens Johnson syndrome. Toxic epidermal necrolysis. 2024. Available at https://rarediseases.org. Accessed on 6th July, 2024.

Oakley AM, Krishnamurthy K. Stevens-Johnson Syndrome. National institutes of health (NIH) (.gov); available at https://www.ncbi.nlm.nih.gov. Accessed on 3rd July, 2024.

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orph J Rare Dis. 2010;5:39.

Bastuji-Garin S, Fouchard N, Bertocchi M. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.

Shrestha O, Pant P, Devkota N, Gurung D, Shrestha D B. Carbamazepine induced toxic epidermal necrolysis and Stevens-Johnson syndrome overlapping during pregnancy in a South-East Asian patient: A case report. Anna Med Surg. 2021;68(10):10-6.

Yang SC, Hu S, Zhang SZ, Huang JW, Zhang J, Ji C, Cheng B. Corrigendum to The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. J Immunol Res. 2018;8:415-45.

Safiri S, Ashrafi-Asgarabad A. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs: Comment on data sparsity. Epilepsia. 2018;59(5):1083-4.

Parrillo SJ, Parrillo CV. Stevens-Johnson syndrome. Available at: http://www.emedicine.com. Accessed on 17TH December 2020.

Mayo Clinic. Stevens-Johnson syndrome. 2010 Available at: https://www.mayoclinic.org. Accessed on 17th March 2024.

Stevens-Johnson syndrome/toxic epidermal necrolysis. 2020. Available at: www.medlineplus.gov. Accessed on 17th March 2024.

Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(4):441-6.

Nasir SA, Tan HL, Tan HJ, Hussaini HM, Ramli R, Stevens-Johnson syndrome following failure of genetic screening prior to carbamazepine prescription, Case Reports in Dentistry. 2017;5:4201357.

Ferguson NN, Rosenbach K, Wanat R, Micheletti L. Taylor, Stevens-Johnson syndrome/toxic epidermal necrolysis inpatient dermatology. Springer. 2018;10:978-9.

National Organization for Rare Disorders. 2020. Available at: https://rarediseases.org/rare-disease. Accessed on 17th March 2024.

Wong A, Malvestiti AA, Hafner MFS. Stevens-Johnson Syndrome and toxic epidermal necrolysis: a review, Revista da Associação Médica Brasileira. 2016;62(5):468-73.

Zhang S, Tang S, Li S, Pan Y, Ding Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. J Dermatolog Treat. 2020;31(1):66-73.

Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126:272–6.

Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in united states adults. J Invest Dermatol. 2016;136(7):1387-97.